Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

103 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Vitamin and mineral supplements: do we really need them?
Kamangar F, Emadi A. Kamangar F, et al. Among authors: emadi a. Int J Prev Med. 2012 Mar;3(3):221-6. Int J Prev Med. 2012. PMID: 22448315 Free PMC article.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT. Narayan R, et al. Among authors: emadi a. Cancer. 2020 Mar 15;126(6):1264-1273. doi: 10.1002/cncr.32657. Epub 2019 Dec 20. Cancer. 2020. PMID: 31860140 Clinical Trial.
Among the 22 patients enrolled on the trial, the composite response rate was 36%, with a composite response rate of 42% noted among those who received the highest dose of BV. ...The authors examined the combination of brentuximab vedotin, an antibody product that recognize …
Among the 22 patients enrolled on the trial, the composite response rate was 36%, with a composite response rate of 42% noted among t …
Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH, Rajan R, Emadi A. Alshemmari SH, et al. Among authors: emadi a. Med Princ Pract. 2016;25(6):501-509. doi: 10.1159/000450956. Epub 2016 Sep 21. Med Princ Pract. 2016. PMID: 27756071 Free PMC article. Review.
Primary myelofibrosis (PMF) is a rare chronic BCR-ABL1-negative myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, inefficient hematopoiesis, and shortened survival. ...Patients with triple-negative PMF have a higher incidence of leukemic …
Primary myelofibrosis (PMF) is a rare chronic BCR-ABL1-negative myeloproliferative neoplasm characterized by progressive bone marrow …
Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics.
Lee MH, Lapidus RG, Ferraris D, Emadi A. Lee MH, et al. Among authors: emadi a. Molecules. 2019 Aug 28;24(17):3121. doi: 10.3390/molecules24173121. Molecules. 2019. PMID: 31466259 Free PMC article. Review.
Acute myeloid leukemia (AML) is a neoplastic disorder resulting from clonal proliferation of poorly differentiated immature myeloid cells. ...Subsequently, selective targeting of redox homeostasis in a molecularly heterogeneous disease, such as AML, has been an appe …
Acute myeloid leukemia (AML) is a neoplastic disorder resulting from clonal proliferation of poorly differentiated immature myeloid c …
Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.
Holtzman NG, El Chaer F, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A. Holtzman NG, et al. Among authors: emadi a. Br J Haematol. 2020 Mar;188(6):881-887. doi: 10.1111/bjh.16261. Epub 2019 Dec 5. Br J Haematol. 2020. PMID: 31804722
PBB-RC during induction chemotherapy is predictive of D14BM clearance, CR, and OS, and can therefore serve as a prognostic marker for clinical outcomes in AML....
PBB-RC during induction chemotherapy is predictive of D14BM clearance, CR, and OS, and can therefore serve as a prognostic marker for …
Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore.
Li AY, Kashanian SM, Hambley BC, Zacholski K, Baer MR, Duong VH, El Chaer F, Holtzman NG, Norsworthy KJ, Levis MJ, Smith BD, Kamangar F, Ghiaur G, Emadi A. Li AY, et al. Among authors: emadi a. Leuk Lymphoma. 2020 Jun 14:1-5. doi: 10.1080/10428194.2020.1775209. Online ahead of print. Leuk Lymphoma. 2020. PMID: 32536282 No abstract available.
Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia.
Patzke CL, Duffy AP, Duong VH, El Chaer F, Trovato JA, Baer MR, Bentzen SM, Emadi A. Patzke CL, et al. Among authors: emadi a. J Clin Med. 2020 Feb 16;9(2):536. doi: 10.3390/jcm9020536. J Clin Med. 2020. PMID: 32079074 Free PMC article.
Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.
Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M. Ross AE, et al. Among authors: emadi a. BJU Int. 2011 Aug;108(3):447-54. doi: 10.1111/j.1464-410X.2010.09907.x. Epub 2010 Dec 22. BJU Int. 2011. PMID: 21176082 Free PMC article.
CONCLUSIONS: • Dimeric naphthoquinones represent a new class of compounds with prostate cancer cytotoxicity and synergistic effects with radiation. ...
CONCLUSIONS: • Dimeric naphthoquinones represent a new class of compounds with prostate cancer cytotoxicity and synergistic effects w …
A chemical genetic screen for modulators of asymmetrical 2,2'-dimeric naphthoquinones cytotoxicity in yeast.
Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M. Emadi A, et al. PLoS One. 2010 May 26;5(5):e10846. doi: 10.1371/journal.pone.0010846. PLoS One. 2010. PMID: 20520766 Free PMC article.
In order to gain insight into the mode of action of binaphthoquinones we performed a systematic high-throughput screen in a yeast isogenic deletion mutant array for enhanced or suppressed growth in the presence of binaphthoquinones. ...Drug sensitivity and resistanc …
In order to gain insight into the mode of action of binaphthoquinones we performed a systematic high-throughput screen in a ye …
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Emadi A, et al. Exp Hematol. 2014 Apr;42(4):247-51. doi: 10.1016/j.exphem.2013.12.001. Epub 2013 Dec 11. Exp Hematol. 2014. PMID: 24333121
We sought to exploit this glutamine addiction therapeutically in mutant IDH primary AML cells from patients by measuring cell growth after exposure to a small molecule glutaminase inhibitor, BPTES. ...This study lays the groundwork for strategies to target a specifi …
We sought to exploit this glutamine addiction therapeutically in mutant IDH primary AML cells from patients by measuring cell growth after e …
103 results
Jump to page
Feedback